Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
LONDON, Nov. 19, 2013 /PRNewswire/ — Edison Investment Research, a leading international investment research firm, announces the launch of full coverage of Onconova Therapeutics, a NASDAQ-listed clinical-stage bio-pharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer.
Edison’s comprehensive report, ONTIME to deliver, was published on 15 October and examines the investment case for the development of rigosertib (IV). The report highlights that if rigosertib (IV) meets its primary endpoint in the ONTIME Phase III trial in higher-risk, second-line MDS in Q114, Onconova could be in a position to file its first NDA next year.
The analysis by Edison’s healthcare team indicates this would represent something to which few recent IPO companies could aspire. Oral rigosertib, which is in Phase II trials for lower-risk MDS, could open a much larger market if positive Phase II data are confirmed in a pivotal trial. With three drug candidates in clinical trials, six active preclinical programmes and cash beyond 2014, Onconova appears to be an attractive investment. We value the company at $476m, or $22.3/share.
For the full report see: www.edisoninvestmentresearch.com/research/company/onconova-therapeutics
The launch of coverage on Onconova Therapeutics is part of a programme of research initiations on bio-pharmaceutical companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its healthcare research team has a range of coverage across small-, mid- and large-cap companies. All reports published by Edison are available to download free of charge from its website www.edisongroup.com.
About Edison Investment Research
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information please contact: Jason Zhang Edison Investment Research +1 646 653 7027 email@example.com
About Onconova Therapeutics
Onconova Therapeutics is a clinical-stage bio-pharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, it has created an extensive library of targeted anti-cancer agents.
SOURCE Edison Investment Research